Floatz logo

Onartuzumab

Non-Squamous Non-Small Cell Lung Cancer

Hoffmann-La Rochemonoclonal_antibodyPhase 3Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

1206 Active assets in the Non-Squamous Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB

View all 50 →

Same molecule, other indications

Onartuzumab is also rated in:

neoplasmDormant
B
Indicative ·
59 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →